Hepatitis D (Delta) virus

Fields Virology: Sixth Edition

Volumn 1, Issue , 2013, Pages

  Taylor, John M ^a   Purcell, Robert H ^c   Farci, Patrizia ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84974688399     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (203)

1. Abbas Z, Jafri W, Raza S. Hepatitis D: scenario in the Asia-Pacific region. World J Gastroenterol 2010;16:554-562.
2. Abou-Jaoude G, Sureau C. Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange. J Virol 2007;81:13057-13066.
3. Alves C, Cheng H, Roder H, et al. Intrinsic disorder and oligomerization of the hepatitis delta virus antigen. Virology 2010;407:333-340.
4. Alves C, Freitas N, Cunha C. Characterization of the nuclear localization signal of the hepatitis delta virus antigen. Virology 2008;370:12-21.
5. Arakawa Y, Moriyama M, Taira M, et al. Molecular analysis of hepatitis D virus infection in Miyako Island, a small Japanese island. J Viral Hepat 2000;7:375-381.
6. Arribas J, Gonzalez-Garcia J, Lorenzo A, et al. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain. AIDS 2005;19:1361-1365.
7. Aslan N, Yurdaydin C, Wiegand J, et al. Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat 2006;13:505-514.
8. Barrera A, Guerra B, Lee H, et al. Analysis of host range phenotypes of primate hepadnaviruses by in vitro infections of hepatitis D virus pseudotypes. J Virol 2004;78:5233-5243.
9. Battegay M, Simpson LH, Hoofnagle JH, et al. Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis. J Med Virol 1994;44:389-392.
10. Bergmann KF, Gerin JL. Antigens of hepatitis delta virus in the liver and serum of humans and animals. J Infect Dis 1986;154:702-706.
11. Bichko V, Netter HJ, Taylor J. Introduction of hepatitis delta virus into animal cell lines via cationic liposomes. J Virol 1994;68:5247-5252.
12. Bissig KD, Wieland SF, Tran P, et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 2010;120:924-930.
13. Bonino F, Heermann KH, Rizzetto M, et al. Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope. J Virol 1986;58:945-950.
14. Bordier BB, Ohkanda J, Liu P, et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest 2003;112:407-414.
15. Borghesio E, Rosina F, Smedile A, et al. Serum immunoglobulin M antibody to hepatitis D as a surrogate marker of hepatitis D in interferon-treated patients and in patients who underwent liver transplantation. Hepatology 1998;27:873-876.
16. Borresen ML, Olsen OR, Ladefoged K, et al. Hepatitis D outbreak among children in a hepatitis B hyper-endemic settlement in Greenland. J Viral Hepat 2010;17:162-170.
17. Boyd A, Lacombe K, Miailhes P, et al. Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus. J Viral Hepat 2009;17:65-76.
18. Breiner KM, Schaller H, Knolle PA. Endothelial cell-mediated uptake of a hepatitis B virus: a new concept of liver targeting of hepatotropic microorganisms. Hepatology 2001;34:803-808.
19. Buti M, Homs M, Rodriguez-Frias F, et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat 2011;18(6):434-442.
20. Buti M, Jardi R, Allende H, et al. Chronic delta hepatitis: is the prognosis worse when associated with hepatitis C virus and human immunodeficiency virus infections? J Med Virol 1996;49:66-69.
21. Caccamo L, Agnelli F, Reggiani P, et al. Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis delta virus coinfection. Transplantation 2007;83:1341-1344.
22. Canbakan B, Senturk H, Tabak F, et al. Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial. J Gastroenterol Hepatol 2006;21:657-663.
23. Cao D, Haussecker D, Huang Y, et al. Combined proteomic-RNAi screen for host factors involved in human hepatitis delta virus replication. RNA 2009;15:1971-1979.
24. Caredda F, Rossi E, d'Arminio Monforte A, et al. Hepatitis B virus-associated coinfection and superinfection with delta agent: indistinguishable disease with different outcome. J Infect Dis 1985;151:925-928.
25. Casey JL. Hepatitis delta virus RNA editing. In: Handa H, Yamaguchi Y, eds. Hepatitis Delta Virus. Georgetown, TX: Landes Bioscience; 2006:52-65.
26. Casey JL, Brown TL, Colan EJ, et al. A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci U S A 1993;90:9016-9020.
27. Casey JL, Niro GA, Engle RE, et al. Hepatitis B virus/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F. J Infect Dis 1996;174:920-926.
28. Castellares C, Barreiro P, Martin-Carbonero L, et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat 2008;15:165-172.
29. Castelnau C, Le Gal F, Ripault MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006;44:728-735.
30. Chang J, Gudima SO, Tarn C, et al. Development of a novel system to study hepatitis delta virus genome replication. J Virol 2005;79:8182-8188.
31. Chang J, Nie X, Chang HE, et al. Transcription of hepatitis delta virus RNA by RNA polymerase II. J Virol 2008;82:1118-1127.
32. Chang J, Provost P, Taylor JM. Resistance of human hepatitis delta virus RNAs to dicer activity. J Virol 2003;77:11910-11917.
33. Chang J, Sigal LJ, Lerro A, et al. Replication of the human hepatitis delta virus genome is initiated in mouse hepatocytes following intravenous injection of naked DNA or RNA sequences. J Virol 2001;75:3469-3473.
34. Chang J, Taylor J. In vivo RNA-directed transcription, with template switching, by a mammalian RNA polymerase. EMBO J 2002;21:157-164.
35. Chang J, Taylor JM. Susceptibility of human hepatitis delta virus RNAs to small interfering RNA action. J Virol 2003;77:9728-9731.
36. Chang M-F, Chang SC, Chang C-I, et al. Nuclear localization signals, but not putative leucine zipper motifs, are essential for nuclear transport of hepatitis delta antigen. J Virol 1992;66:6019-6027.
37. Chao M, Hsieh S-Y, Taylor J. Role of two forms of the hepatitis delta virus antigen: evidence for a mechanism of self-limiting genome replication. J Virol 1990;64:5066-5069.
38. Chao M, Hsieh S-Y, Taylor J. The antigen of hepatitis delta virus: examination of in vitro RNA-binding specificity. J Virol 1991;65:4057-4062.
39. Chen P-J, Kalpana G, Goldberg J, et al. Structure and replication of the genome of hepatitis D virus. Proc Natl Acad Sci U S A 1986;83:8774-8778.
40. Chen TZ, Wu JC, Au LC, et al. Specific inhibition of delta antigen by in vitro system by antisense oligodeoxynucleotide: implications for translation mechanism and treatment. J Virol Methods 1997;65:183-189.
41. Chia JS, Wu HL, Wang HW, et al. Inhibition of hepatitis delta virus genomic ribozyme self-cleavage by aminoglycosides. J Biomed Sci 1997;4:208-216.
42. Choi SH, Jeong SH, Hwang SB. Large hepatitis delta antigen modulates transforming growth factor-beta signaling cascades: implication of hepatitis delta virus-induced liver fibrosis. Gastroenterology 2007;132:343-357.
43. Cole S, Gowans EJ, Macnaughton TB, et al. Direct evidence for cytotoxicity associated with expression of hepatitis delta virus antigen. Hepatology 1991;13:845-851.
44. Cross TJ, Rizzi P, Horner M, et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol 2008;80:277-282.
45. D'Ugo E, Paroli M, Palmieri G, et al. Immunization of woodchucks with adjuvanted sHDAg (p24): immune response and outcome following challenge. Vaccine 2004;22:457-466.
46. Dalekos GN, Galanakis E, Zervou E, et al. Interferon-alpha treatment of children with chronic hepatitis D virus infection: the Greek experience. Hepatogastroenterology 2000;47:1072-1076.
47. Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ 2009;58:1-27.
48. Degertekin H, Yalcin K, Yakut M. The prevalence of hepatitis delta virus infection in acute and chronic liver diseases in Turkey: an analysis of clinical studies. Turk J Gastroenterol 2006;17:25-34.
49. Deny P. Hepatitis delta virus genetic variability: from genotypes I, II, III to eight major clades. In: Casey JL, ed. Hepatitis Delta Virus. Heidelberg, Germany: Springer; 2006:151-171.
50. Di Marco V, Giacchino R, Timitilli A, et al. Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study. J Viral Hepat 1996;3:123-128.
51. Eigen M. Selforganization of matter and the evolution of biological macromolecules. Naturwissenschaften 1971;58:465-523.
52. Erhardt A, Gerlich W, Starke C, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 2006;26:805-810.
53. Farci P. Hepatitis D. In: Dooley JS, Lok ASF, Burroughs AK, et al, eds. Sherlock's Diseases of the Liver and Biliary System. 12th ed. Indianapolis: Wiley-Blackwell; 2011:393-405.
54. Farci P. Treatment of chronic hepatitis D: new advances, old challenges. Hepatology 2006;44:536-539.
55. Farci P, Gerin JL, Aragona M, et al. Diagnostic and prognostic significance of the IgM antibody to the hepatitis delta virus. J Am Med Assoc 1986;255:1443-1446.
56. Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994;330:88-94.
57. Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004;126:1740-1749.
58. Farci P, Smedile A, Lavarini C, et al. Delta hepatitis in inapparent carriers of hepatitis B surface antigen. A disease simulating acute hepatitis B progressive to chronicity. Gastroenterology 1983;85:669-673.
59. Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut 2000;46:420-426.
60. Ferre-D'Amare AR, Scott WG. Small self-cleaving ribozymes. Cold Spring Harb Perspect Biol 2010;2(10):a003574.
61. Ferre-D'Amare AR, Zhou K, Doudna JA. Crystal structure of a hepatitis delta virus ribozyme. Nature 1998;395:567-574.
62. Fiedler M, Roggendorf M. Vaccination against hepatitis delta virus infection: studies in the woodchuck (Marmota monax) model. Intervirology 2001;44:154-161.
63. Flint SJ, Enquist LW, Racaniello VR, et al. Principles of Virology. 3rd ed. Washington: ASM Press; 2009.
64. Flodgren E, Bengtsson S, Knutsson M, et al. Recent high incidence of fulminant hepatitis in Samara, Russia: molecular analysis of prevailing hepatitis B and D virus strains. J Clin Microbiol 2000;38:3311-3316.
65. Flores R, Gas M-E, Molina-Serrano D, et al. Viroid replication: rolling-circles, enzymes, and ribozymes. Viruses 2009;1:317-334.
66. Gaeta GB, Stroffolini T, Chiaramonte M, et al. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology 2000;32:824-827.
67. Gaeta GB, Stroffolini T, Smedile A, et al. Hepatitis delta in Europe: vanishing or refreshing? Hepatology 2007;46:1312-1313.
68. Gaudin JL, Faure P, Godinot H, et al. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. Liver 1995;15:45-52.
69. Glenn JS, Watson JA, Havel CM, et al. Identification of a prenylation site in the delta virus large antigen. Science 1992;256:1331-1333.
70. Gomes-Gouvea MS, Soares MC, Bensabath G, et al. Hepatitis B virus and hepatitis delta virus genotypes in outbreaks of fulminant hepatitis (Labrea black fever) in the western Brazilian Amazon region. J Gen Virol 2009;90:2638-2643.
71. Greco-Stewart VS, Miron P, Abrahem A, et al. The human RNA polymerase II interacts with the terminal stem-loop regions of the hepatitis delta virus RNA genome. Virology 2007;357:68-78.
72. Greco-Stewart VS, Pelchat M. Interaction of host cellular proteins with components of the hepatitis delta virus. Viruses 2010;2:189-212.
73. Greco-Stewart VS, Schissel E, Pelchat M. The hepatitis delta virus RNA genome interacts with the human RNA polymerases I and III. Virology 2009;386:12-15.
74. Gripon P, Rumin S, Urban S, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 2002;99:15655-15660.
75. Gudima S, He Y, Meier A, et al. Assembly of hepatitis delta virus: particle characterization, including the ability to infect primary human hepatocytes. J Virol 2007;81:3608-3617.
76. Gunsar F, Akarka H, Erdsoz G, et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther 2005;10:721-726.
77. Hadziyannis SJ. Review: hepatitis delta virus. J Gastroenterol Hepatol 1997;12:289-298.
78. He L-F, Ford E, Purcell RH, et al. The size of the hepatitis delta agent. J Med Virol 1989;27:31-33.
79. Heidrich B, Deterding K, Tillmann HL, et al. Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat 2009;16:883-894.
80. Holmberg SD, Ward JW. Hepatitis delta: seek and ye shall find. J Infect Dis 2010;202:822-824.
81. Hsu SC, Syu WJ, Ting LT, et al. Immunohistochemical differentiation of hepatitis D virus genotypes. Hepatology 2000;32:1111-1116.
82. Huang W-H, Chen C-W, Wu H-L, et al. Post-translational modification of delta antigen of hepatitis D virus. In: Casey JL, ed. Hepatitis Delta Virus. Heidelberg, Germany: Springer-Verlag; 2006:91-112.
83. Huang YH, Tao MH, Hu CP, et al. Identification of novel HLA-A*0201-restricted CD8+ T-cell epitopes on hepatitis delta virus. J Gen Virol 2004;85:3089-3098.
84. Huo TI, Wu JC, Wu SI, et al. Changing seroepidemiology of hepatitis B, C, and D virus infections in high-risk populations. J Med Virol 2004;72:41-45.
85. Jardi R, Rodriguez F, Buti M, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001;34:404-410.
86. Jenna S, Sureau C. Effect of mutations in the small envelope protein of hepatitis B virus on assembly and secretion of hepatitis delta virus. Virology 1998;251:176-186.
87. Kaymakoglu S, Karaca C, Demir K, et al. Alpha interferon and ribavirin combination therapy of chronic hepatitis D. Antimicrob Agents Chemother 2005;49:1135-1138.
88. Ke A, Zhou K, Ding F, et al. A conformational switch controls hepatitis delta virus ribozyme catalysis. Nature 2004;429:201-205.
89. King A, Lefkowitz E, Adams M, et al, eds. Ninth Report of the International Committee on Taxonomy of Viruses. Philadelphia: Elsevier; 2011.
90. Komla-Soukha I, Sureau C. A tryptophan-rich motif in the carboxyl terminus of the small envelope protein of hepatitis B virus is central to the assembly of hepatitis delta virus particles. J Virol 2006;80:4648-4655.
91. Kucirka LM, Farzadegan H, Feld JJ, et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis 2010;202:845-852.
92. Kuo MY-P, Goldberg J, Coates L, et al. Molecular cloning of hepatitis delta virus RNA from an infected woodchuck liver: sequence, structure, and applications. J Virol 1988;62:1855-1861.
93. Kuo MYP, Sharmeen L, Dinter-Gottlieb G, et al. Characterization of self-cleaving RNA sequences on the genome and antigenome of human hepatitis delta virus. J Virol 1988;62:4439-4444.
94. Lau DT, Doo E, Park Y, et al. Lamivudine for chronic delta hepatitis. Hepatology 1999;30:546-549.
95. Lau DT, Kleiner DE, Park Y, et al. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology 1999;117:1229-1233.
96. Lau JY, King R, Tibbs CJ, et al. Loss of HBsAg with interferon-alpha therapy in chronic hepatitis D virus infection. J Med Virol 1993;39:292-296.
97. Le Gal F, Castelnau C, Gault E, et al. Reply. Hepatology. 2007;45:1332-1333.
98. Le Gal F, Gordien E, Affolabi D, et al. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. J Clin Microbiol 2005;43:2363-2369.
99. Lee CM, Bih FY, Chao YC, et al. Evolution of hepatitis delta virus RNA during chronic infection. J Virol 1992;188:265-273.
100. Leistner CM, Gruen-Bernhard S, Glebe D. Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell Microbiol 2008;10:122-133.
101. Liao FT, Lee YJ, Ko JL, et al. Hepatitis delta virus epigenetically enhances clusterin expression via histone acetylation in human hepatocellular carcinoma cells. J Gen Virol 2009;90:1124-1134.
102. Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995;22:1101-1108.
103. Lu SN, Chen TM, Lee CM, et al. Molecular epidemiological and clinical aspects of hepatitis D virus in a unique triple hepatitis viruses (B, C, D) endemic community in Taiwan. J Med Virol 2003;70:74-80.
104. Manesis EK, Schina M, Le Gal F, et al. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Antivir Ther 2007;12:381-388.
105. Manock SR, Kelley PM, Hyams KC, et al. An outbreak of fulminant hepatitis delta in the Waorani, an indigenous people of the Amazon basin of Ecuador. Am J Trop Med Hyg 2000;63:209-213.
106. Mederacke I, Bremer B, Heidrich B, et al. Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol 2010;48:2022-2029.
107. Modahl LE, Lai MM. Hepatitis delta virus: the molecular basis of laboratory diagnosis. Crit Rev Clin Lab Sci 2000;37:45-92.
108. Navascues CA, Rodriguez M, Sotorrio NG, et al. Epidemiology of hepatitis D virus infection: changes in the last 14 years. Am J Gastroenterol 1995;90:1981-1984.
109. Negro F, Bergmann KF, Baroudy BM, et al. Chronic hepatitis delta virus (HDV) infection in hepatitis B virus carrier chimpanzees experimentally superinfected with HDV. J Infect Dis 1988;158:151-159.
110. Negro F, Pacchioni D, Bussolati G, et al. Pathobiology of hepatitis delta virus infection at the cell level. Prog Clin Biol Res 1993;382:155-160.
111. Negro F, Shapiro M, Satterfield WC, et al. Reappearance of hepatitis D virus (HDV) replication in chronic hepatitis B virus carrier chimpanzees rechallenged with HDV. J Infect Dis 1989;160:567-571.
112. Netter HJ, Kajino K, Taylor J. Experimental transmission of human hepatitis delta virus to the laboratory mouse. J Virol 1993;67:3357-3362.
113. Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006;44:713-720.
114. Niro GA, Gravinese E, Martini E, et al. Clearance of hepatitis B surface antigen in chronic carriers of hepatitis delta antibodies. Liver 2001;21:254-259.
115. Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. J Viral Hepat 2005;12:2-9.
116. Niro GA, Smedile A, Ippolito AM, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol 2010;53:834-840.
117. Nisini R, Paroli M, Accapezzato D, et al. Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. J Virol 1997;71:2241-2251.
118. Obermayer-Straub P, Manns MP. Hepatitis C and D, retroviruses and autoimmune manifestations. J Autoimmun 2001;16:275-285.
119. Ottobrelli A, Marzano A, Smedile A, et al. Patterns of hepatitis delta virus reinfection and disease in liver transplantation. Gastroenterology 1991;101:1649-1655.
120. Oyunsuren T, Kurbanov F, Tanaka Y, et al. High frequency of hepatocellular carcinoma in Mongolia; association with mono-, or co-infection with hepatitis C, B, and delta viruses. J Med Virol 2006;78:1688-1695.
121. Park CY, Oh SH, Kang SM, Lim YS, Hwang SB. Hepatitis delta virus large antigen sensitizes to TNF-alpha-induced NF-kappaB signaling. Mol Cells. 2009;28:49-55.
122. Pollicino T, Raffa G, Santantonio T, et al. Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses. J Virol 2011;85:432-439.
123. Polo JM, Jeng K-S, Lim B, et al. Transgenic mice support replication of hepatitis delta virus RNA in multiple tissues, particularly in skeletal muscle. J Virol 1995;69:4880-4887.
124. Ponzetto A, Cote PJ, Popper H, et al. Transmission of the hepatitis B virus-associated delta agent to the eastern woodchuck. Proc Natl Acad Sci U S A 1984;81:2208-2212.
125. Ponzetto A, Hoyer BH, Popper H, et al. Titration of infectivity of hepatitis D virus in chimpanzees. J Infect Dis 1987;155:72-78.
126. Popper H, Thung SN, Gerber MA, et al. Histologic studies of severe delta agent infection in Venezuelan Indians. Hepatology 1983;3:906-912.
127. Pugnale P, Pazienza V, Guilloux K, et al. Hepatitis delta virus inhibits alpha interferon signaling. Hepatology 2009;49:398-406.
128. Puoti M, Rossi S, Forleo MA, et al. Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection. J Hepatol 1998;29:45-52.
129. Purcell RH, Scatterfield WC, Bergmann KF, et al. Experimental hepatitis delta virus infection in the chimpanzee. Prog Clin Biol Res 1987;234:27-36.
130. Radjef N, Gordien E, Ivaniushina V, et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol 2004;78:2537-2544.
131. Raimondo G, Brunetto MR, Pontisso P, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 2006;43:100-107.
132. Reid CE, Lazinski DW. A host-specific function is required for ligation of a wide variety of ribozyme-processed RNAs. Proc Natl Acad Sci U S A 2000;97:424-429.
133. Rizzetto M. Hepatitis D: thirty years after. J Hepatol 2009;50:1043-1050.
134. Rizzetto M. The delta agent. J Hepatol 1983;3:729-737.
135. Rizzetto M, Canese MG, Arico J, et al. Immunofluorescence detection of a new antigen-antibody system associated to the hepatitis B virus in the liver and in the serum of HBsAg carriers. Gut 1977;18:997-1003.
136. Rizzetto M, Canese MG, Gerin JL, et al. Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J Infect Dis 1980;141:590-602.
137. Rizzetto M, Hoyer B, Canese MG, et al. Delta agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci U S A 1980;77:6124-6128.
138. Rizzetto M, Purcell RH, Gerin JL. Epidemiology of HBV-associated delta agent: geographical distribution of anti-δ and polytransfused HBsAg carriers. Lancet 1980;1:1215-1218.
139. Rizzetto M, Shih JW, Gerin JL. The hepatitis B virus-associated delta antigen: isolation from liver, development of solid-phase radioimmunoassays for delta antigen and anti-delta and partial characterization of delta antigen. J Immunol 1980;125:318-324.
140. Rizzetto M, Smedile A. Hepatitis D. In: Schiff ER, Sorrell M, Maddrey W, eds. Diseases of the Liver. Philadelphia: Lippincot Williams and Wilkins; 2002:863-875.
141. Rizzetto M, Verme G, Recchia S, et al. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med 1983;98:437-441.
142. Rocheleau L, Pelchat M. The subviral RNA database: a toolbox for viroids, the hepatitis delta virus and satellite RNAs research. BMC Microbiol 2006;6:24.
143. Roingeard P, Dubois F, Marcellin P, et al. Persistent delta antigenaemia in chronic delta hepatitis and its relation with human immunodeficiency virus infection. J Med Virol 1992;38:191-194.
144. Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009;136:1629-1638.
145. Rosina F, Conoscitore P, Cuppone R, et al. Changing pattern of chronic hepatitis D in southern Europe. Gastroenterology 1999;117:161-166.
146. Rosina F, Saracco G, Rizzetto M. Risk of post-transfusion infection with the hepatitis delta virus. A multicenter study. N Engl J Med 1985;312:1488-1491.
147. Ryu W-S, Bayer M, Taylor J. Assembly of hepatitis delta virus particles. J Virol 1992;66:2310-2315.
148. Sagnelli E, Coppola N, Scolastico C, et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology 2000;32:1106-1110.
149. Sakugawa H, Nakasone H, Nakayoshi T, et al. Hepatitis B virus concentrations in serum determined by sensitive quantitative assays in patients with established chronic hepatitis delta virus infection. J Med Virol 2001;65:478-484.
150. Samuel D, Feray C, Bismuth H. Hepatitis viruses and liver transplantation. J Gastroenterol Hepatol 1997;12:S335-S341.
151. Samuel D, Zignego AL, Reynes M, et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 1995;21:333-339.
152. Sanchez-Tapias JM, Mas A, Costa J, et al. Recombinant alpha 2c-interferon therapy in fulminant viral hepatitis. J Hepatol 1987;5:205-210.
153. Schaper M, Rodriguez-Frias F, Jardi R, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol 2010;52:658-664.
154. Schulze A, Gripon P, Urban S. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 2007;46:1759-1768.
155. Schulze A, Schieck A, Ni Y, et al. Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J Virol 2009;84:1989-2000.
156. Sharmeen L, Kuo MY, Taylor J. Self-ligating RNA sequences on the antigenome of human hepatitis delta virus. J Virol 1989;63:1428-1430.
157. Shih HH, Jeng KS, Syu WJ, et al. Hepatitis B surface antigen levels and sequences of natural hepatitis B virus variants influence the assembly and secretion of hepatitis D virus. J Virol 2008;82:2250-2264.
158. Smedile A, Casey JL, Cote PJ, et al. Hepatitis D viremia following orthotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope. Hepatology 1998;27:1723-1729.
159. Smedile A, Ciancio A, Rizzetto M. Hepatitis D. In: Richmann DD, Whitley RJ, Hayden FG, eds. Clinical Virology: Hepatitis Delta Virus. Washington, DC: ASM Press; 2002:1227-1240.
160. Smedile A, Farci P, Verme G, et al. Influence of delta infection on severity of hepatitis B. Lancet 1982;2:945-947.
161. Stroffolini T, Almasio PL, Sagnelli E, et al. Evolving clinical landscape of chronic hepatitis B: a multicenter Italian study. J Med Virol 2009;81:1999-2006.
162. Su AI, Pezacki JP, Wodicka L, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 2002;99:15669-15674.
163. Su CW, Huang YH, Huo TI, et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology 2006;130:1625-1635.
164. Sureau C. The use of hepatocytes to investigate HDV infection: the HDV/HepaRG model. Methods Mol Biol 2010;640:463-473.
165. Sureau C, Guerra B, Lanford RE. Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis delta virion. J Virol 1993;67:366-372.
166. Sureau C, Guerra B, Lee H. The middle hepatitis B virus envelope protein is not necessary for infectivity of hepatitis delta virus. J Virol 1994;68:4063-4066.
167. Taylor J, Pelchat M. Origin of hepatitis δ virus. Fut Microbiol 2010;5:393-402.
168. Taylor JM. Hepatitis delta virus. Virology 2006;344:71-76.
169. Taylor JM. Replication of the hepatitis delta virus RNA genome. Adv Vir Res 2009;74:102-121.
170. Taylor JM. Structure and replication of HDV RNA. Curr Top Microbiol Immunol 2006;307:1-23.
171. Taylor JM, Han Z. Purinergic receptor functionality is necessary for infection of human hepatocytes by hepatitis delta virus and hepatitis B virus. PLoS One 2010;5:1-5.
172. Troisi CL, Hollinger FB, Hoots WK, et al. A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993;81:412-418.
173. Tsatsralt-Od B, Takahashi M, Endo K, et al. Prevalence of hepatitis B, C, and delta virus infections among children in Mongolia: progress in childhood immunization. J Med Virol 2007;79:1064-1074.
174. Tseng C-H, Lai MMC. Hepatitis delta virus RNA replication. Viruses 2009;1:818-831.
175. Tseng CH, Cheng TS, Shu CY, et al. Modification of small hepatitis delta virus antigen by SUMO protein. J Virol 2010;84:918-927.
176. Urban S. New insights into hepatitis B and hepatitis delta virus entry. Future Virol 2008;3:253-264.
177. Uzunalimoglu O, Yurdaydin C, Cetinkaya H, et al. Risk factors for hepatocellular carcinoma in Turkey. Dig Dis Sci 2001;46:1022-1028.
178. Verme G, Brunetto MR, Oliveri F, et al. Role of hepatitis delta virus infection in hepatocellular carcinoma. Dig Dis Sci 1991;36:1134-1136.
179. Wang D, Pearlberg J, Liu YT, et al. Deleterious effects of hepatitis delta virus replication on host cell proliferation. J Virol 2001;75:3600-3604.
180. Wang K-S, Choo Q-L, Weiner AJ, et al. Structure, sequence and expression of the hepatitis delta viral genome. Nature 1986;323:508-513.
181. Wang TC, Chao M. RNA recombination of hepatitis delta virus in natural mixed-genotype infection and transfected cultured cells. J Virol 2005;79:2221-2229.
182. Watanabe T, Sorensen EM, Naito A, et al. Involvement of host cellular multivesicular body functions in hepatitis B virus budding. Proc Natl Acad Sci U S A 2007;104:10205-10210.
183. Webb C-HT, Riccitelli NJ, Ruminski DJ, et al. Widespread occurrence of self-cleaving ribozymes. Science 2009;326:953.
184. Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection-not a vanishing disease in Europe! Hepatology 2007;45:1331-1332.
185. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010;7:31-40.
186. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011;364:322-331.
187. Weltman MD, Brotodihardjo A, Crewe EB, et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995;2:39-45.
188. Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol 2005;79:9369-9380.
189. Williams V, Brichler S, Radjef N, et al. Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene. J Gen Virol 2009;90:2759-2767.
190. Wolters LM, van Nunen AB, Honkoop P, et al. Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat 2000;7:428-434.
191. Wu J. Functional and clinical significance of hepatitis D vius genotype II infection. Curr Top Microbiol Immunol 2006;307:173-186.
192. Wu JC, Chiang TY, Shiue WK, et al. Recombination of hepatitis D virus RNA sequences and its implications. Mol Biol Evol 1999;16:1622-1632.
193. Wu JC, Wang YJ, Hwang SJ, et al. Hepatitis D virus infection among prostitutes in Taiwan. J Gastroenterol Hepatol 1993;8:334-337.
194. Xia Y-P, Yeh C-T, Ou J-S, et al. Characterization of nuclear targeting signal of hepatitis delta antigen: nuclear transport as a protein complex. J Virol 1992;66:914-921.
195. Yamaguchi K, Handa H. Hepatitis delta antigen and RNA polymerase II. In: Handa H, Yamada S, eds. Hepatitis Delta Virus. Georgetown TX: Landes Bioscience; 2006:66-75.
196. Yamaguchi Y, Mura T, Chanarat S, et al. Hepatitis delta antigen binds to the clamp of RNA polymerase II and affects transcriptional fidelity. Genes Cells 2007;12:863-875.
197. Yamashiro T, Nagayama K, Enomoto N, et al. Quantitation of the level of hepatitis delta virus RNA in serum, by real-time polymerase chain reaction-and its possible correlation with the clinical stage of liver disease. J Infect Dis 2004;189:1151-1157.
198. Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 2012;1:e00049.
199. Yurdaydin C, Bozkaya H, Gurel S, et al. Famciclovir treatment of chronic delta hepatitis. J Hepatol 2002;37:266-271.
200. Yurdaydin C, Bozkaya H, Karaaslan H, et al. A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis. J Viral Hepat 2007;14:812-816.
201. Yurdaydin C, Bozkaya H, Onder FO, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat 2008;15:314-321.
202. Zachou K, Yurdaydin C, Drebber U, et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int 2009;30:430-437.
203. Zuccola HJ, Rozzelle JE, Lemon SM, et al. Structural basis of the oligomerization of hepatitis delta antigen. Structure 1998;6:821-830.